Challenges and opportunities for meningococcal vaccination in the developing world

References

• Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17. doi:10.1186/1478-7954-11-17. PMID:24016339.
   PubMed Web of Science ®Google Scholar
• Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(Suppl 2):B3–9. doi:10.1016/j.vaccine.2011.12.062. PMID:22607896.
   PubMed Web of Science ®Google Scholar
• Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, Harnden A, Mant D, Levin M. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397–403. doi:10.1016/S0140-6736(06)67932-4. PMID:16458763.
   PubMed Web of Science ®Google Scholar
• Hart CA, Thomson AP. Meningococcal disease and its management in children. BMJ. 2006;333(7570):685–90. doi:10.1136/bmj.38968.683958.AE. PMID:17008668.
   PubMedGoogle Scholar
• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20. doi:10.1007/978-1-61779-346-2_1. PMID:21993636.
   PubMedGoogle Scholar
• Branco RG, Amoretti CF, Tasker RC. Meningococcal disease and meningitis. J Pediatr (Rio J). 2007;83(2 Suppl):S46–53. doi:10.2223/JPED.1612. PMID:17486194.
   PubMed Web of Science ®Google Scholar
• Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19(4):566–73. doi:10.3201/eid1904.111799. PMID:23628376.
   PubMed Web of Science ®Google Scholar
• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of Meningococcal vaccines. J Adolesc Health. 2016;59(2 Suppl):S3–S11. doi:10.1016/j.jadohealth.2016.04.012. PMID:27449148.
   PubMed Web of Science ®Google Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196–210. doi:10.1016/S0140-6736(07)61016-2. PMID:17604802.
   PubMed Web of Science ®Google Scholar
• van de Beek D. Progress and challenges in bacterial meningitis. Lancet. 2012;380(9854):1623–4. doi:10.1016/S0140-6736(12)61808-X. PMID:23141602.
   PubMed Web of Science ®Google Scholar
• Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(5):317–28. doi:10.1016/S1473-3099(10)70048-7. PMID:20417414.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184–91. doi:10.1086/649209. PMID:20001736.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR–2):1–28. PMID:23515099.
   PubMed Web of Science ®Google Scholar
• Bilukha O, Messonnier N, Fischer M. Use of meningococcal vaccines in the United States. Pediatr Infect Dis J. 2007;26(5):371–6. doi:10.1097/01.inf.0000259996.95965.ef. PMID:17468644.
   PubMed Web of Science ®Google Scholar
• Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA. 2001;286(6):688–93. doi:10.1001/jama.286.6.688. PMID:11495618.
   PubMed Web of Science ®Google Scholar
• Shibl A, Tufenkeji H, Khalil M, Memish Z, Meningococcal Leadership Forum Expert G. Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region. J Epidemiol Glob Health. 2012;2(1):23–30. doi:10.1016/j.jegh.2012.02.002. PMID:23856395.
   PubMedGoogle Scholar
• Liphaus BL, Cappeletti-Goncalves-Okai MI, Silva-Delemos AP, Gorla MC, Rodriguez-Fernandes M, Pacola MR, Fernandez-Collucci MÂ, Matsumoto-Shinkai IA, Takenori-Higa F, Ferreira-Catani C, et al. Outbreak of Neisseria meningitidis C in a Brazilian oil refinery involving an adjacent community. Enferm Infecc Microbiol Clin. 2013;31(2):88–92. doi:10.1016/j.eimc.2012.05.009. PMID:22943834.
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–61. doi:10.1016/S1473-3099(10)70251-6. PMID:21075057.
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–63. doi:10.1016/j.vaccine.2009.04.063. PMID:19477562.
   PubMed Web of Science ®Google Scholar
• Centers for Disease ControlPrevention. Meningococcal disease. Surveillance. 2017. Available from: https://http://www.cdc.gov/meningococcal/surveillance/index.html.
   Google Scholar
• Riou JY, Djibo S, Sangare L, Lombart JP, Fagot P, Chippaux JP, Guibourdenche M. A predictable comeback: the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995. Bull World Health Organ. 1996;74(2):181–7. PMID:8706234.
   PubMed Web of Science ®Google Scholar
• Nelson SJ, Charlett A, Orr HJ, Barker RM, Neal KR, Taylor C, Monk PN, Evans MR, Stuart JM. Risk factors for meningococcal disease in university halls of residence. Epidemiol Infect. 2001;126(2):211–7. PMID:11349971.
   PubMed Web of Science ®Google Scholar
• Sidikou F, Zaneidou M, Alkassoum I, Schwartz S, Issaka B, Obama R, Lingani C, Tate A, Ake F, Sakande S, et al. Emergence of epidemic Neisseria meningitidis serogroup C in Niger, 2015: an analysis of national surveillance data. Lancet Infect Dis. 2016;16(11):1288–94. doi:10.1016/S1473-3099(16)30253-5. PMID:27567107.
   PubMed Web of Science ®Google Scholar
• Guibourdenche M, Hoiby EA, Riou JY, Varaine F, Joguet C, Caugant DA. Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989–94. Epidemiol Infect. 1996;116(2):115–20. doi:10.1017/S095026880005233X. PMID:8620901.
   PubMed Web of Science ®Google Scholar
• Bhatt KM, Bhatt SM, Mirza NB. Meningococcal meningitis. East Afr Med J. 1996;73(1):35–9. PMID:8625860.
   PubMed Web of Science ®Google Scholar
• Hart CA, Cuevas LE. Meningococcal disease in Africa. Ann Trop Med Parasitol. 1997;91(7):777–85. doi:10.1080/00034983.1997.11813203. PMID:9625934.
   PubMed Web of Science ®Google Scholar
• Chang Q, Tzeng YL, Stephens DS. Meningococcal disease: changes in epidemiology and prevention. Clin Epidemiol. 2012;4:237–45. doi:10.2147/CLEP.S28410. PMID:23071402.
   PubMedGoogle Scholar
• Lingani C, Bergeron-Caron C, Stuart JM, Fernandez K, Djingarey MH, Ronveaux O, Schnitzler JC, Perea WA. Meningococcal meningitis surveillance in the African Meningitis Belt, 2004–2013. Clin Infect Dis. 2015;61(Suppl 5):S410–5. doi:10.1093/cid/civ597. PMID:26553668.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, Ronveaux O, Préziosi MP, Stuart JM. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. Lancet Infect Dis. 2017;17(8):867–72. doi:10.1016/S1473-3099(17)30301-8. PMID:28545721.
   PubMed Web of Science ®Google Scholar
• Campbell H, Ladhani S. The importance of surveillance: Group W meningococcal disease outbreak response and control in England. Int Health. 2016;8(6):369–71. doi:10.1093/inthealth/ihw037. PMID:27620924.
   PubMed Web of Science ®Google Scholar
• Broker M, Emonet S, Fazio C, Jacobsson S, Koliou M, Kuusi M, Pace D, Paragi M, Pysik A, Simões MJ, et al. Meningococcal serogroup Y disease in Europe: continuation of high importance in some European regions in 2013. Hum Vaccin Immunother. 2015;11(9):2281–6. doi:10.1080/21645515.2015.1051276. PMID:26036710.
   PubMed Web of Science ®Google Scholar
• CDC. Active Bacterial Core Surveillance Report. Emerging Infections Program Network, Neisseria meningitidis. 2015.
   Google Scholar
• Tsang RSW, Deeks SL, Wong K, Marchand-Austin A, FB J. Invasive serogroup W Neisseria meningitidis (MenW) in Ontario, Canada shows potential clonal replacement during the period January 1, 2009 – June 30, 2016. Can Comm Dis Rep. 2016;42(12):263–6.
   PubMedGoogle Scholar
• Tsang RSW, Hoang L, Tyrrell GJ, Horsman G, Van Caeseele P, Jamieson F, Lefebvre B, Haldane D, Gad RR, German GJ, et al. Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009–2016. Can Commun Dis Rep. 2017;43(7/8):144–9.
   PubMedGoogle Scholar
• Crum-Cianflone N, Sullivan E. Meningococcal vaccinations. Infect Dis Ther. 2016;5(2):89–112. doi:10.1007/s40121-016-0107-0. PMID:27086142.
   PubMed Web of Science ®Google Scholar
• Abad R, Lopez EL, Debbag R, Vazquez JA. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect. 2014;142(12):2461–70. doi:10.1017/S0950268814001149. PMID:24831052.
   PubMed Web of Science ®Google Scholar
• Aguilera JF, Perrocheau A, Meffre C, Hahne S, Group WW. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis. 2002;8(8):761–7. doi:10.3201/eid0805.010422. PMID:12141959.
   PubMed Web of Science ®Google Scholar
• Epidemic meningitis control in countries of the African meningitis belt, 2016. Wkly Epidemiol Rec. 2017;92(13):145–54. PMID:28361528.
   PubMedGoogle Scholar
• Lahra MM, for the National Neisseria Network A. Australian Meningococcal Surveillance Programme, 1 January to 31 March 2017. Commun Dis Intell Q Rep. 2017;41(2):E201. PMID:28899315.
   PubMed Web of Science ®Google Scholar
• Martin NV, Ong KS, Howden BP, Lahra MM, Lambert SB, Beard FH, Dowse GK, Saul N, Communicable Diseases Network Australia MenW Working Group. Rise in invasive serogroup W meningococcal disease in Australia 2013–2015. Commun Dis Intell Q Rep. 2016;40(4):E454–E9. PMID:28043219.
   PubMedGoogle Scholar
• Ceyhan M, Anis S, Htun-Myint L, Pawinski R, Soriano-Gabarro M, Vyse A. Meningococcal disease in the Middle East and North Africa: an important public health consideration that requires further attention. Int J Infect Dis. 2012;16(8):e574–82. doi:10.1016/j.ijid.2012.03.011. PMID:22647750.
   PubMed Web of Science ®Google Scholar
• Borrow R, Alarcon P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16(4):313–28. doi:10.1080/14760584.2017.1258308. PMID:27820969.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364(9431):365–7. doi:10.1016/S0140-6736(04)16725-1. PMID:15276396.
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 2001;357(9251):195–6. doi:10.1016/S0140-6736(00)03594-7. PMID:11213098.
   PubMed Web of Science ®Google Scholar
• Bose A, Coen P, Tully J, Viner R, Booy R. Effectiveness of meningococcal C conjugate vaccine in teenagers in England. Lancet. 2003;361(9358):675–6. doi:10.1016/S0140-6736(03)12563-9. PMID:12606181.
   PubMed Web of Science ®Google Scholar
• Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17(5):840–7. doi:10.1128/CVI.00529-09. PMID:20219881.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Beebeejaun K, Lucidarme J, Campbell H, Gray S, Kaczmarski E, Ramsay ME, Borrow R. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578–85. doi:10.1093/cid/ciu881. PMID:25389259.
   PubMed Web of Science ®Google Scholar
• Mustapha MM, Marsh JW, Krauland MG, Fernandez JO, de Lemos AP, Dunning Hotopp JC, Wang X, Mayer LW, Lawrence JG, Hiller NL, et al. Genomic investigation reveals highly conserved, mosaic, recombination events associated with capsular switching among invasive Neisseria meningitidis Serogroup W Sequence Type (ST)-11 strains. Genome Biol Evol. 2016;8(6):2065–75. doi:10.1093/gbe/evw122. PMID:27289093.
   PubMed Web of Science ®Google Scholar
• Safadi MA, Bettinger JA, Maturana GM, Enwere G, Borrow R, Global Meningococcal I. Evolving meningococcal immunization strategies. Expert Rev Vaccines. 2015;14(4):505–17. doi:10.1586/14760584.2015.979799. PMID:25494168.
   PubMed Web of Science ®Google Scholar
• Safadi MA, O'Ryan M, Valenzuela Bravo MT, Brandileone MC, Gorla MC, de Lemos AP, Moreno G, Vazquez JA, López EL, Taha MK, et al. The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations. Vaccine. 2015;33(48):6529–36. doi:10.1016/j.vaccine.2015.10.055. PMID:26597036.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, Wang X, Messonnier NE, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2):2016–2193. doi:10.1542/peds.2016-2193. PMID:28100689.
   PubMed Web of Science ®Google Scholar
• Broderick MP, Faix DJ, Hansen CJ, Blair PJ. Trends in meningococcal disease in the United States military, 1971–2010. Emerg Infect Dis. 2012;18(9):1430–7. doi:10.3201/eid1809.120257. PMID:22932005.
   PubMed Web of Science ®Google Scholar
• Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Preziosi MP, Elie C, Findlow H, Carlone G, Borrow R, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine. 2007;25(Suppl 1):A101–7. doi:10.1016/j.vaccine.2007.04.050. PMID:17532101.
   PubMedGoogle Scholar
• Kristiansen PA, Diomande F, Ba AK, Sanou I, Ouedraogo AS, Ouedraogo R, Sangaré L, Kandolo D, Aké F, Saga IM, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013;56(3):354–63. doi:10.1093/cid/cis892. PMID:23087396.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–82. doi:10.1016/S0140-6736(16)31921-3. PMID:28100432.
   PubMed Web of Science ®Google Scholar
• Wang NY, Pollard AJ. The next chapter for group B meningococcal vaccines. Crit Rev Microbiol. 2017;44(1):1–17. doi:10.1080/1040841X.2017.1329276. PMID:28557577.
   PubMed Web of Science ®Google Scholar
• Grogan J, Roos K. Serogroup B meningococcus outbreaks, prevalence, and the case for standard vaccination. Curr Infect Dis Rep. 2017;19(9):30. doi:10.1007/s11908-017-0587-4. PMID:28770496.
   PubMed Web of Science ®Google Scholar
• Basta NE, Mahmoud AA, Wolfson J, Ploss A, Heller BL, Hanna S, Johnsen P, Izzo R, Grenfell BT, Findlow J, et al. Immunogenicity of a Meningococcal B Vaccine during a University Outbreak. N Engl J Med. 2016;375(3):220–8. doi:10.1056/NEJMoa1514866. PMID:27468058.
   PubMed Web of Science ®Google Scholar
• Kuhdari P, Stefanati A, Lupi S, Valente N, Gabutti G. Meningococcal B vaccination: real-world experience and future perspectives. Pathog Glob Health. 2016;110(4–5):148–56. doi:10.1080/20477724.2016.1195072. PMID:27309042.
   PubMed Web of Science ®Google Scholar
• Findlow J. Vaccines for the prevention of meningococcal capsular group B disease: what have we recently learned? Hum Vaccin Immunother. 2016;12(1):235–8. doi:10.1080/21645515.2015.1091131. PMID:26619037.
   PubMed Web of Science ®Google Scholar
• Ali A, Jafri RZ, Messonnier N, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global practices of meningococcal vaccine use and impact on invasive disease. Pathog Glob Health. 2014;108(1):11–20. doi:10.1179/2047773214Y.0000000126. PMID:24548156.
   PubMed Web of Science ®Google Scholar
• World Bank Country and Lending Groups - Country Classification. 2017.
   Google Scholar
• Broutin H, Philippon S, Constantin de Magny G, Courel MF, Sultan B, Guegan JF. Comparative study of meningitis dynamics across nine African countries: a global perspective. Int J Health Geogr. 2007;6:29. doi:10.1186/1476-072X-6-29. PMID:17623084.
   PubMed Web of Science ®Google Scholar
• Dbaibo G, Tatochenko V, Wutzler P. Issues in pediatric vaccine-preventable diseases in low- to middle-income countries. Hum Vaccin Immunother. 2016;12(9):2365–77. doi:10.1080/21645515.2016.1181243. PMID:27322436.
   PubMed Web of Science ®Google Scholar
• Gabutti G, Stefanati A, Kuhdari P. Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage. J Prev Med Hyg. 2015;56(3):E116–20. PMID:26788731.
   PubMedGoogle Scholar
• Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Sáfadi MA. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26–36. doi:10.1016/j.vaccine.2011.12.032. PMID:22178525.
   PubMed Web of Science ®Google Scholar
• Fukusumi M, Kamiya H, Takahashi H, Kanai M, Hachisu Y, Saitoh T, Ohnishi M, Oishi K, Sunagawa T. National surveillance for meningococcal disease in Japan, 1999–2014. Vaccine. 2016;34(34):4068–71. doi:10.1016/j.vaccine.2016.06.018. PMID:27291085.
   PubMed Web of Science ®Google Scholar
• Chiou CS, Liao JC, Liao TL, Li CC, Chou CY, Chang HL, Yao SM, Lee YS. Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan. BMC Infect Dis. 2006;6:25. doi:10.1186/1471-2334-6-25. PMID:16478548.
   PubMed Web of Science ®Google Scholar
• Invasive Meningococcal Disease - National Surveillance Report. Australian Government Department of Health; 2017. p. 1–8.
   Google Scholar
• World Health Organization – Emergencies preparedness, response – Meningococcal disease [4/10/17]. Available from: http://www.who.int/entity/csr/don/archive/disease/meningococcal_disease/en/index.html.
   Google Scholar
• Abstracts - The European Meningococcal Disease Society. Austria. 2013.
   Google Scholar
• Safadi MA, Cintra OA. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res. 2010;32(3):263–71. doi:10.1179/016164110X12644252260754. PMID:20406604.
   PubMed Web of Science ®Google Scholar
• Perez AE, Dickinson FO, Rodriguez M. Community acquired bacterial meningitis in Cuba: a follow up of a decade. BMC Infect Dis. 2010;10:130. doi:10.1186/1471-2334-10-130. PMID:20500858.
   PubMed Web of Science ®Google Scholar
• Mendsaikhan J, Watt JP, Mansoor O, Suvdmaa N, Edmond K, Litt DJ, Nymadawa P, Baoping Y, Altantsetseg D, Slack M. Childhood bacterial meningitis in Ulaanbaatar, Mongolia, 2002–2004. Clin Infect Dis. 2009;48(Suppl 2):S141–6. doi:10.1086/596493. PMID:19191628.
   PubMedGoogle Scholar
• Sinclair D, Preziosi MP, Jacob John T, Greenwood B. The epidemiology of meningococcal disease in India. Trop Med Int Health. 2010;15(12):1421–35. doi:10.1111/j.1365-3156.2010.02660.x. PMID:21054695.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Regional Office for the Eastern Mediterranea (EMRO) – Country profiles 2008. Available from: http://www.emro.who.int/emrinfo.
   Google Scholar
• Yemen Ministry of Health. Annual statistical health report 2009. 2009. Available from: http://www.mophp-ye.org/arabic/docs/Report2009.pdf.
   Google Scholar
• Afifi S, Wasfy MO, Azab MA, Youssef FG, Pimentel G, Graham TW, Mansour H, Elsayed N, Earhart K, Hajjeh R, et al. Laboratory-based surveillance of patients with bacterial meningitis in Egypt (1998–2004). Eur J Clin Microbiol Infect Dis. 2007;26(5):331–40. doi:10.1007/s10096-007-0280-x. PMID:17404766.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Yildirim I, Balmer P, Borrow R, Dikici B, Turgut M, Kurt N, Aydogan A, Ecevit C, Anlar Y, et al. A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis. 2008;14(7):1089–96. doi:10.3201/eid1407.070938. PMID:18598630.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Gurler N, Ozsurekci Y, Keser M, Aycan AE, Gurbuz V, Salman N, Camcioglu Y, Dinleyici EC, Ozkan S, et al. Meningitis caused by Neisseria Meningitidis, Hemophilus Influenzae Type B and Streptococcus Pneumoniae during 2005–2012 in Turkey. A multicenter prospective surveillance study. Hum Vaccin Immunother. 2014;10(9):2706–12. doi:10.4161/hv.29678. PMID:25483487.
   PubMed Web of Science ®Google Scholar
• Borrow R, Lee JS, Vazquez JA, Enwere G, Taha MK, Kamiya H, Kim HM, Jo DS, Global Meningococcal Initiative. Meningococcal disease in the Asia-Pacific region: findings and recommendations from the Global Meningococcal Initiative. Vaccine. 2016;34(48):5855–62. doi:10.1016/j.vaccine.2016.10.022. PMID:27780631.
   PubMed Web of Science ®Google Scholar
• Bahrain Ministry of Health. Health statistics 2007. Available from: http://www.moh.gov.bh/PDF/Publications/Statistics/hs2007/pdf/CH07-publi-chealth_2007.pdf.
   Google Scholar
• World Health Organization. Control of epidemic meningococcal disease. WHO practical guidelines. 2nd ed. Available from: http://www.who.int/csr/resources/publications/meningitis/whoemcbac983.pdf.
   Google Scholar
• Greenwood B. Editorial: 100 years of epidemic meningitis in West Africa – has anything changed? Trop Med Int Health. 2006;11(6):773–80. doi:10.1111/j.1365-3156.2006.01639.x. PMID:16771997.
   PubMed Web of Science ®Google Scholar
• Mohammed I, Iliyasu G, Habib AG. Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa. Pathog Glob Health. 2017;111(1):1–6. doi:10.1080/20477724.2016.1274068. PMID:28081671.
   PubMed Web of Science ®Google Scholar
• Borrow R, Caugant DA, Ceyhan M, Christensen H, Dinleyici EC, Findlow J, Glennie L, Von Gottberg A, Kechrid A, Vázquez Moreno J, et al. Meningococcal disease in the Middle East and Africa: Findings and updates from the Global Meningococcal Initiative. J Infect. 2017;75(1):1–11. doi:10.1016/j.jinf.2017.04.007. PMID:28455205.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Ozsurekci Y, Gurler N, Karadag Oncel E, Camcioglu Y, Salman N, Celik M, Emiroglu MK, Akin F, Tezer H, et al. Bacterial agents causing meningitis during 2013–2014 in Turkey: A multi-center hospital-based prospective surveillance study. Hum Vaccin Immunother. 2016;12(11):2940–5. doi:10.1080/21645515.2016.1209278. PMID:27454468.
   PubMed Web of Science ®Google Scholar
• Dickinson FO, Perez AE. Bacterial meningitis in children and adolescents: an observational study based on the national surveillance system. BMC Infect Dis. 2005;5:103. doi:10.1186/1471-2334-5-103. PMID:16288649.
   PubMed Web of Science ®Google Scholar
• Velez-van-Meerbeke A, Medina-Silva, N, Besada-Lombana, Mojica-Madero JA. Epidemiology of meningococcal disease in Colombia. Colombia: Neuroscience (NEUROS) Research Group; 2015. doi:10.1016/j.infect.2016.02.004.
   Google Scholar
• Safadi MA, Berezin EN, Arlant LH. Meningococcal disease: epidemiology and early effects of immunization programs. J Pediatric Infect Dis Soc. 2014;3(2):91–3. doi:10.1093/jpids/piu027. PMID:26625360.
   PubMedGoogle Scholar
• Safadi MA, de los Monteros LE, Lopez EL, Saez-Llorens X, Lemos AP, Moreno-Espinosa S, Ayala SG, Torres JP, de Moraes JC, Vázquez JA. The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative. Expert Rev Vaccines. 2013;12(8):903–15. doi:10.1586/14760584.2013.814879. PMID:23909747.
   PubMed Web of Science ®Google Scholar
• Vyse A, Wolter JM, Chen J, Ng T, Soriano-Gabarro M. Meningococcal disease in Asia: an under-recognized public health burden. Epidemiol Infect. 2011;139(7):967–85. doi:10.1017/S0950268811000574. PMID:21492496.
   PubMed Web of Science ®Google Scholar
• Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385(9966):430–40. doi:10.1016/S0140-6736(14)61698-6. PMID:25280870.
   PubMed Web of Science ®Google Scholar
• Benet T, Picot VS, Awasthi S, Pandey N, Bavdekar A, Kawade A, Robinson A, Rakoto-Andrianarivelo M, Sylla M, Diallo S, et al. Severity of Pneumonia in under 5-year-old children from developing countries: a multicenter, prospective, observational study. Am J Trop Med Hyg. 2017;97(1):68–76. doi:10.4269/ajtmh.16-0733. PMID:28719310.
   PubMed Web of Science ®Google Scholar
• Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. J Infect Dis. 2005;192(Suppl 1):S160–6. doi:10.1086/431504. PMID:16088799.
   PubMedGoogle Scholar
• Esposito S, Principi N. Pneumococcal vaccines and the prevention of community-acquired pneumonia. Pulm Pharmacol Ther. 2015;32:124–9. doi:10.1016/j.pupt.2014.02.003. PMID:24607597.
   PubMed Web of Science ®Google Scholar
• Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis. 2014;14(9):813–9. doi:10.1016/S1473-3099(14)70805-9. PMID:25104307.
   PubMed Web of Science ®Google Scholar
• Pneumococcal conjugate vaccine for childhood immunization–WHO position paper. Wkly Epidemiol Rec. 2007;82(12):93–104. PMID:17380597.
   PubMedGoogle Scholar
• Haemophilus influenzae type b (Hib) Vaccination Position Paper – July 2013. Wkly Epidemiol Rec. 2013;88(39):413–26. PMID:24143842.
   PubMedGoogle Scholar
• Yezli S, Bin Saeed AA, Assiri AM, Alhakeem RF, Yunus MA, Turkistani AM, Booy R, Alotaibi BM. Prevention of meningococcal disease during the Hajj and Umrah mass gatherings: past and current measures and future prospects. Int J Infect Dis. 2016;47:71–8. doi:10.1016/j.ijid.2015.12.010. PMID:26707071.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213–20. doi:10.1038/nri2494. PMID:19214194.
   PubMed Web of Science ®Google Scholar
• Broker M, Cooper B, Detora LM, Stoddard JJ. Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease. Infect Drug Resist. 2011;4:137–47. doi:10.2147/IDR.S12716. PMID:21904459.
   PubMedGoogle Scholar
• Patton ME, Stephens D, Moore K, MacNeil JR. Updated recommendations for use of MenB-FHbp Serogroup B Meningococcal Vaccine – advisory committee on immunization practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509–13. doi:10.15585/mmwr.mm6619a6. PMID:28520709.
   PubMed Web of Science ®Google Scholar
• Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362(16):1511–20. doi:10.1056/NEJMra0906357. PMID:20410516.
   PubMed Web of Science ®Google Scholar
• Meningococcal Polysaccharide Vaccine Bivalent AC or Trivalent ACW. 2005.
   Google Scholar
• Meningococcal Vaccines: Market & Supply Update 2015. 1–9]. Available from: https://http://www.unicef.org/supply/files/Meningitis_Vaccine_Market_Supply_Update.pdf.
   Google Scholar
• European Medicines Agency. Nimenrix: summary of product characteristics. GlaskoSmithKline; 2017. p. 1–65.
   Google Scholar
• NeisVac-C® (meningococcal group C-TT conjugate vaccine, adsorbed) Product Monograph. Pfizer Canada Inc.; 2015. p. 1–23.
   Google Scholar
• Product Information - Meningitec - Meningococcal Serogroup C Conjugate Vaccine. Pfizer Australia Pty Ltd; 2011. p. 1–9.
   Google Scholar
• Menjugate®Liquid - Product Monograph. GSK Canada. 2015:1–22.
   Google Scholar
• Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst Rev. 2005;(1):CD001093. doi:10.1002/14651858.CD001093.pub2. PMID:15674874.
   PubMed Web of Science ®Google Scholar
• World Health Organization – Meningococcal disease in the African Meningitis Belt. epidemic season 2006. 2006 [6/10/17]. Available from: http://www.who.int/csr/don/2006_03_21/en/.
   Google Scholar
• The use of polysaccharide trivalent ACW vaccine for the control of epidemic meningococcal disease outbreaks in countries of the African meningitis belt. Switzerland: World Health Organization; 2003.
   Google Scholar
• Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis. 2010;50(Suppl 2):S45–53. doi:10.1086/648964. PMID:20144016.
   PubMed Web of Science ®Google Scholar
• Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 2010;9(3):285–98. doi:10.1586/erv.10.3. PMID:20218857.
   PubMed Web of Science ®Google Scholar
• Baxter R, Keshavan P, Welsch JA, Han L, Smolenov I. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants. Hum Vaccin Immunother. 2016;12(5):1300–10. doi:10.1080/21645515.2015.1136040. PMID:26829877.
   PubMed Web of Science ®Google Scholar
• Erlich KS, Congeni BL. Importance of circulating antibodies in protection against meningococcal disease. Hum Vaccin Immunother. 2012;8(8):1029–35. doi:10.4161/hv.20473. PMID:22854672.
   PubMed Web of Science ®Google Scholar
• Merino Arribas JM, Carmona Martinez A, Horn M, Perez Porcuna XM, Otero Reigada MD, Mares Bermudez J, Centeno Malfaz F, Miranda M, Mendez M, Garcia Cabezas MA, et al. Safety and immunogenicity of the quadrivalent Meningococcal Serogroups A, C, W and Y tetanus toxoid conjugate vaccine coadministered with routine childhood vaccines in European Infants: an open, randomized trial. Pediatr Infect Dis J. 2017;36(4):e98–e107. doi:10.1097/INF.0000000000001484. PMID:28002359.
   PubMed Web of Science ®Google Scholar
• Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo GS. Review of meningococcal vaccines with updates on immunization in adults. Hum Vaccin Immunother. 2014;10(4):995–1007. PMID:24500529.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease PreventionControl. Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA. Stockholm: ECDC; 2017.
   Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin Stacey W. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–6. PMID:26492381.
   PubMed Web of Science ®Google Scholar
• Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE, Active Bacterial Core Surveillance Team. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. 2008;46(1):1–13. doi:10.1086/524041. PMID:18171206.
   PubMed Web of Science ®Google Scholar
• Scott RD, 2nd, Meltzer MI, Erickson LJ, De Wals P, Rosenstein NE. Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis. Am J Prev Med. 2002;23(2):98–105. PMID:12121797.
   PubMed Web of Science ®Google Scholar
• Shepard CW, Ortega-Sanchez IR, Scott RD, 2nd, Rosenstein NE, Team AB. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005;115(5):1220–32. doi:10.1542/peds.2004-2514. PMID:15867028.
   PubMed Web of Science ®Google Scholar
• De Voer RM, Mollema L, Schepp RM, de Greeff SC, PG vG. Immunity against Neisseria meningitides serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine. PLoS One. 2010;5(e12144).
   PubMedGoogle Scholar
• Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ. Meningococcal serogroup A, C, W(1)(3)(5) and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLoS One. 2013;8(5):e65036. doi:10.1371/journal.pone.0065036. PMID:23741448.
   PubMed Web of Science ®Google Scholar
• De Wals P, Zhou Z. Cost-effectiveness comparison of monovalent C versus quadrivalent ACWY meningococcal conjugate vaccination in Canada. Pediatr Infect Dis J. 2017;36(7):e203–e7. doi:10.1097/INF.0000000000001512. PMID:28027288.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease PreventionControl: Surveillance of invasive bacterial diseases in Europe 2008/2009. Stockholm 2011. 1–136.
   Google Scholar
• Ladhani SN, Ramsay M, Borrow R, Riordan A, Watson JM, Pollard AJ. Enter B and W: two new meningococcal vaccine programmes launched. Arch Dis Child. 2016;101(1):91–5. doi:10.1136/archdischild-2015-308928. PMID:26672098.
   PubMed Web of Science ®Google Scholar
• Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccin. 2011;7(2):170–82. doi:10.4161/hv.7.2.13717. PMID:21178398.
   PubMed Web of Science ®Google Scholar
• Panatto D, Amicizia D, Lai PL, Gasparini R. Neisseria meningitidis B vaccines. Expert Rev Vaccines. 2011;10(9):1337–51. doi:10.1586/erv.11.103. PMID:21919622.
   PubMed Web of Science ®Google Scholar
• JCVI position statement on use of Bexsero® meningococcal B vaccine in the UK. 2014.
   Google Scholar
• Gasparini R, Landa P, Amicizia D, Icardi G, Ricciardi W, de Waure C, Tanfani E, Bonanni P, Lucioni C, Testi A, et al. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero(R)) against meningococcal B disease: a cost-effectiveness analysis. Hum Vaccin Immunother. 2016;12(8):2148–61. doi:10.1080/21645515.2016.1160177. PMID:27163398.
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter CL. Modelling the cost-effectiveness of catch-up ‘MenB’ (Bexsero) vaccination in England. Vaccine. 2017;35(2):208–11. doi:10.1016/j.vaccine.2016.11.076. PMID:27923519.
   PubMed Web of Science ®Google Scholar
• de Soarez PC, Sartori AM, de Andrade Lagoa Nobrega L, Itria A, Novaes HM. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil. Value Health. 2011;14(8):1019–27. doi:10.1016/j.jval.2011.05.045. PMID:22152170.
   PubMed Web of Science ®Google Scholar
• Parent du Chatelet I, Gessner BD, da Silva A. Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis. Vaccine. 2001;19(25–26):3420–31. doi:10.1016/S0264-410X(01)00066-4. PMID:11348706.
   PubMed Web of Science ®Google Scholar
• LaForce M. Introduction of a group A meningococcal conjugate vaccine in sub-Saharan Africa: Cost/savings analysis. MVP unpublished data. 2008.
   Google Scholar
• Colombini A, Trotter C, Madrid Y, Karachaliou A, Preziosi MP. Costs of Neisseria meningitidis Group A disease and economic impact of vaccination in Burkina Faso. Clin Infect Dis. 2015;61(Suppl 5):S473–82. doi:10.1093/cid/civ600. PMID:26553677.
   PubMedGoogle Scholar
• Assaf-Casals A, Dbaibo G. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix): a review of its immunogenicity, safety, co-administration, and antibody persistence. Hum Vaccin Immunother. 2016;12(7):1825–37. doi:10.1080/21645515.2016.1143157. PMID:26900984.
   PubMed Web of Science ®Google Scholar
• Greenwood B, Chiarot E, MacLennan CA, O'Ryan M. Can we defeat meningococcal disease in low and middle income countries? Vaccine. 2012;30(Suppl 2):B63–6. doi:10.1016/j.vaccine.2011.12.063. PMID:22607901.
   PubMedGoogle Scholar
• Somda ZC, Perry HN, Messonnier NR, Djingarey MH, Ki SO, Meltzer MI. Modeling the cost-effectiveness of the integrated disease surveillance and response (IDSR) system: meningitis in Burkina Faso. PLoS One. 2010;5(9). doi:10.1371/journal.pone.0013044. PMID:20927386.
   PubMed Web of Science ®Google Scholar
• Kulkarni PS, Socquet M, Jadhav SS, Kapre SV, LaForce FM, Poonawalla CS. Challenges and opportunities while developing a Group A meningococcal conjugate vaccine within a product development partnership: a manufacturer's perspective from the Serum Institute of India. Clin Infect Dis. 2015;61(Suppl 5):S483–8. doi:10.1093/cid/civ500. PMID:26553678.
   PubMedGoogle Scholar
• Dougla R, Samant V. The vaccine industry. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 6th ed. Scotland: Saunders Elsevier; 2012. p. 33–43.
   Google Scholar
• Meningitis Vaccine Project. Revolutionary meningitis vaccine breaks another barrier: first to gain approval to travel outside cold chain. Atlanta (GA): Meningitis Vaccine Project; 2012.
   Google Scholar
• Zipursky S, Djingarey MH, Lodjo JC, Olodo L, Tiendrebeogo S, Ronveaux O. Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin. Vaccine. 2014;32(13):1431–5. doi:10.1016/j.vaccine.2014.01.038. PMID:24559895.
   PubMed Web of Science ®Google Scholar